Jerome W Gray
Department of Pathology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232-2561, USA.
Rejuvenation Res. 2006 Summer;9(2):245-55. doi: 10.1089/rej.2006.9.245.
Atherosclerosis is a disease of large- and medium-sized arteries. Complications from atherosclerosis remain a serious cause of morbidity and mortality in industrialized countries. The disease begins very early in life and effects most people in the West. However, because the progression of the disease is slow, symptoms usually do not occur until after the fifth decade of life. Because atherosclerosis is a ubiquitous occurrence throughout the world, as life expectancy is prolonged most populations will see increasing numbers of deaths from complications of atherosclerosis unless there are dramatic advances in treatment. Because it begins so early in life, current treatment is aimed at slowing or reversing the progression of the disease rather than eliminating the initiating steps. Changes in diet and exercise, cholesterol-lowering drugs, and improvements in surgical treatments have made significant inroads into prolonging life, but much work is still required. To proceed further, a better understanding is needed of the underlying causes of disease progression. In this regard, evidence is mounting that the foam cells of the lesion (a critical cell in atherosclerosis progression) exhibit characteristics of an acquired lysosomal storage disorder. In this review the evidence for this conclusion is reviewed and the ramifications of this conclusion are explored with regard to the understanding of disease progression mechanisms, possible improvements in treatment, and their role in increasing life expectancy.
动脉粥样硬化是一种发生于大中型动脉的疾病。在工业化国家,动脉粥样硬化引发的并发症仍是发病和死亡的一个重要原因。这种疾病在生命早期就开始出现,影响着大多数西方人。然而,由于疾病进展缓慢,症状通常直到50岁以后才会出现。由于动脉粥样硬化在世界各地普遍存在,随着预期寿命的延长,除非在治疗方面取得重大进展,大多数人群中因动脉粥样硬化并发症死亡的人数将会增加。由于它在生命早期就开始出现,目前的治疗旨在减缓或逆转疾病的进展,而不是消除起始步骤。饮食和运动的改变、降胆固醇药物以及外科治疗的改进在延长寿命方面已取得显著进展,但仍有大量工作要做。为了进一步推进,需要更好地了解疾病进展的根本原因。在这方面,越来越多的证据表明,病变中的泡沫细胞(动脉粥样硬化进展中的关键细胞)表现出一种获得性溶酶体贮积症的特征。在这篇综述中,我们回顾了支持这一结论的证据,并探讨了该结论对于理解疾病进展机制、可能的治疗改进及其在延长预期寿命中的作用的影响。